{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:09:36Z","timestamp":1789528176166,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study, aimed at determining the effect of ivermectin on scabies, which has recently reached epidemic proportions, was conducted by the Department of Dermatology and Venereology at Dicle University. The study aims to evaluate the success of ivermectin in the treatment of scabies, identify variables affecting this success, and contribute positively to the development of future national treatment protocols. Additionally, the study seeks to test the hypothesis that ivermectin, which is significantly easier to use in cases of failure with topical treatments, is a good first-line treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective study, 412 patients diagnosed with scabies via clinical examination by a specialist physician and recommended a 200\u00a0\u00b5g\/kg dose of ivermectin at one-week intervals, who presented to Dicle University Dermatology and Venereology Clinic between January 1, 2023, and June 30, 2024, were examined. Fifty-two patients whose records lacked the parameters evaluated in the study were excluded. A total of 360 patients were included in the study. Data on children under five years of age, those weighing less than 15\u00a0kg, and pregnant or lactating women were not obtained due to insufficient information regarding oral ivermectin use in these groups. Data were evaluated with SPSS-21.0 statistical program and the value, mean, median value, standard deviation, incidence rate and frequency of each parameter in total patients were recorded. Associations were analysed using Kolmogorov-Smirnov test, dependent t test, Wilcoxon test, Pearson Chi-square (\u03c72) test, Yates Chi-square (\u03c72) test, Fisher Chi-square (\u03c72) test analysis, Mc-Nemar test, Pearson\/spearman correlation analysis, logistic regression analysis. A\n                      <jats:italic>p<\/jats:italic>\n                      -value of &lt;\u20090.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ivermectin treatments for all 360 patients were prescribed by a specialist physician, and 78.6% (283) of the patients benefited from the treatment. Of these 360 patients, 295 (81.94%) had tried at least one other treatment option before ivermectin and did not benefit from it, while 66.1% (43 out of 65) of those who had not previously undergone treatment benefited from ivermectin. Furthermore, 81.36% (240 out of 295) of patients who did not respond to previous treatments benefited from ivermectin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study concluded that ivermectin could be a significant treatment option for patients diagnosed with scabies. The superiority of appropriately dosed ivermectin treatment over other treatments was observed, particularly in patients resistant to other scabies treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11315-5","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T16:27:57Z","timestamp":1753288077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of ivermectin on scabies: a retrospective evaluation"],"prefix":"10.1186","volume":"25","author":[{"given":"\u00d6mer","family":"Karakoyun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-2636","authenticated-orcid":false,"given":"Erhan","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"11315_CR1","doi-asserted-by":"publisher","first-page":"628392","DOI":"10.3389\/fmed.2021.628392","volume":"8","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S, St\u00e4nder S. Itch in scabies: what do we know? Front Med (Lausanne). 2021;8:628392. https:\/\/doi.org\/10.3389\/fmed.2021.628392.","journal-title":"Front Med (Lausanne)"},{"key":"11315_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1573396316666200203164115","volume":"16","author":"AKC Leung","year":"2020","unstructured":"Leung AKC, Lam JM, Leong KF. Scabies: a neglected global disease. Curr Pediatr Rev. 2020;16:33\u201342. https:\/\/doi.org\/10.2174\/1573396316666200203164115.","journal-title":"Curr Pediatr Rev"},{"issue":"9","key":"11315_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/jdv.19167","volume":"37","author":"S Schneider","year":"2023","unstructured":"Schneider S, Wu J, Tizek L, Ziehfreund S, Zink A. Itch intensity in scabies patients: an observational cohort study. J Eur Acad Dermatol Venereol. 2023;37(9):1749\u201357. https:\/\/doi.org\/10.1111\/jdv.19167.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"11315_CR4","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1111\/jdv.17333","volume":"35","author":"C Baykal","year":"2021","unstructured":"Baykal C, Atci T, Kutlay A, Baykut B, T\u00fcrko\u011flu Z. Scabies outbreak in Turkey in 2018\u20132019. J Eur Acad Dermatol Venereol. 2021;35:e384\u20135. https:\/\/doi.org\/10.1111\/jdv.17333.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"11315_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/tmi.14058","volume":"29","author":"S Gupta","year":"2024","unstructured":"Gupta S, Thornley S, Morris A, Sundborn G, Grant C. Prevalence and determinants of scabies: a global systematic review and meta-analysis. Trop Med Int Health. 2024;29(12):1006\u201317. https:\/\/doi.org\/10.1111\/tmi.14058.","journal-title":"Trop Med Int Health"},{"key":"11315_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41182-021-00348-6","volume":"49","author":"AA El-Moamly","year":"2021","unstructured":"El-Moamly AA. Scabies as a part of the world health organization roadmap for neglected tropical diseases 2021\u20132030: what we know and what we need to do for global control. Trop Med Health. 2021;49:64. https:\/\/doi.org\/10.1186\/s41182-021-00348-6.","journal-title":"Trop Med Health"},{"issue":"10","key":"11315_CR7","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/life12101598","volume":"12","author":"M Dela\u0161 A\u017edaji\u0107","year":"2022","unstructured":"Dela\u0161 A\u017edaji\u0107 M, Be\u0161li\u0107 I, Ga\u0161i\u0107 A, Ferara N, Pedi\u0107 L, Lugovi\u0107-Mihi\u0107 L. Increased scabies incidence at the beginning of the 21st century: what do reports from Europe and the world show? Life. 2022;12(10):1598. https:\/\/doi.org\/10.3390\/life12101598.","journal-title":"Life"},{"issue":"21","key":"11315_CR8","doi-asserted-by":"publisher","first-page":"e33805","DOI":"10.1097\/MD.0000000000033805","volume":"102","author":"J Al-Dabbagh","year":"2023","unstructured":"Al-Dabbagh J, Younis RM, Ismail NM. The currently available diagnostic tools and treatments of scabies and scabies variants: an updated narrative review. Medicine. 2023;102(21):e33805. https:\/\/doi.org\/10.1097\/MD.0000000000033805.","journal-title":"Medicine"},{"issue":"1","key":"11315_CR9","first-page":"7","volume":"31","author":"RF Genuino","year":"2022","unstructured":"Genuino RF, Batac MCF, Capule FR, Ednalino KAG, Garcia FB Jr, Ladia MAJ, Santos MP, Yabes AM, Cagayan MSFS. Comparative efficacy and safety of oral ivermectin, topical permethrin, and its combination in the treatment of scabies: a systematic literature review. J Philippine Dermatol Soc. 2022;31(1):7\u201319.","journal-title":"J Philippine Dermatol Soc"},{"key":"11315_CR10","doi-asserted-by":"publisher","unstructured":"Veraldi S, Schianchi R, Nazzaro G. Treatment of permethrin-resistant scabies with pyrethrins\/piperonyl butoxide foam. J Dermatol Treat. 2023;34(1). https:\/\/doi.org\/10.1080\/09546634.2023.2156395.","DOI":"10.1080\/09546634.2023.2156395"},{"key":"11315_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jvc2.289","volume":"3","author":"L Restano","year":"2024","unstructured":"Restano L, Brusasco M, Cappadona C, Monzani NA, Cavalli R. Two-year, single-centre, real-life experience with permethrin 5% and benzyl benzoate 25% in 228 children with scabies: a retrospective report. JEADV Clin Pract. 2024;3:219\u201325. https:\/\/doi.org\/10.1002\/jvc2.289.","journal-title":"JEADV Clin Pract"},{"issue":"18","key":"11315_CR12","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.3390\/jcm13185511","volume":"13","author":"T Simonart","year":"2024","unstructured":"Simonart T, Lam Hoai XL. Escalating threat of drug-resistant human scabies: current insights and future directions. J Clin Med. 2024;13(18):5511. https:\/\/doi.org\/10.3390\/jcm13185511.","journal-title":"J Clin Med"},{"issue":"5","key":"11315_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ad.2022.05.036","volume":"114","author":"JP Velasco-Amador","year":"2023","unstructured":"Velasco-Amador JP, Prados-Carmona A, Ruiz-Villaverde R. Resistance to permethrin in scabies treatment: does it really exist? Actas Dermosifiliogr. 2023;114(5):433\u20134. https:\/\/doi.org\/10.1016\/j.ad.2022.05.036.","journal-title":"Actas Dermosifiliogr"},{"issue":"12","key":"11315_CR14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1111\/ijd.17327","volume":"63","author":"S Uzun","year":"2024","unstructured":"Uzun S, Durdu M, Y\u00fcrekli A, et al. Clinical practice guidelines for the diagnosis and treatment of scabies. Int J Dermatol. 2024;63(12):1642\u201356. https:\/\/doi.org\/10.1111\/ijd.17327.","journal-title":"Int J Dermatol"},{"issue":"3","key":"11315_CR15","first-page":"325","volume":"15","author":"LH Kircik","year":"2016","unstructured":"Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325\u201332.","journal-title":"J Drugs Dermatol"},{"key":"11315_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1610-0387.2006.05941.x","volume":"4","author":"H Hamm","year":"2006","unstructured":"Hamm H, Beiteke U, Hoger PH, et al. Treatment of scabies with 5% permethrin cream: results of a German multicenter study. J Dtsch Dermatol Ges. 2006;4:407\u201313.","journal-title":"J Dtsch Dermatol Ges"},{"key":"11315_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1525-1470.1990.tb01078.x","volume":"7","author":"D Taplin","year":"1990","unstructured":"Taplin D, Meinking TL, Chen JA, Sanchez R. Comparison of cro-tamiton 10% cream (Eurax) and permethrin 5% cream (Elimite) for the treatment of scabies in children. Pediatr Dermatol. 1990;7:67\u201373.","journal-title":"Pediatr Dermatol"},{"key":"11315_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/bjd.12454","volume":"169","author":"C B\u00e9court","year":"2013","unstructured":"B\u00e9court C, Marguet C, Balguerie X, Joly P. Treatment of scabies with oral Ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Br J Dermatol. 2013;169:931\u20133.","journal-title":"Br J Dermatol"},{"key":"11315_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/S0190-9622(83)70168-4","volume":"9","author":"D Taplin","year":"1983","unstructured":"Taplin D, Rivera A, Walker JG, et al. A comparative trial of three treatment schedules for the eradication of scabies. J Am Acad Dermatol. 1983;9:550\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"11315_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0190-9622(86)70263-6","volume":"15","author":"PD Taplin","year":"1986","unstructured":"Taplin PD, Meinking TL, Porcelain SL, et al. Permethrin 5% dermal cream: a new treatment for scabies. J Am Acad Dermatol. 1986;15:995\u20131001.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"11315_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/ced\/llac092","volume":"48","author":"R Balestri","year":"2023","unstructured":"Balestri R, Magnano M, Infusino SD, Girardelli CR, Ioris T, Rech G. Oral Ivermectin to treat scabies: a comparison of two different regimens. Clin Exp Dermatol. 2023;48(3):232\u20134. https:\/\/doi.org\/10.1093\/ced\/llac092.","journal-title":"Clin Exp Dermatol"},{"key":"11315_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/jdv.14351","volume":"31","author":"CM Salavastru","year":"2017","unstructured":"Salavastru CM, Chosidow O, Boffa MJ, et al. European guideline for the management of scabies. J Eur Acad Dermatol Venereol. 2017;31:1248\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"11315_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2471\/BLT.08.052308","volume":"87","author":"F Ly","year":"2009","unstructured":"Ly F, Caumes E, Ndaw CA, Ndiaye B, Mah\u00e9 A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in dakar, senegal: a randomized controlled trial. Bull World Health Organ. 2009;87:424\u201330.","journal-title":"Bull World Health Organ"},{"issue":"4","key":"11315_CR24","first-page":"189","volume":"59","author":"MR Ranjkesh","year":"2013","unstructured":"Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral Ivermectin for the treatment of scabies. Ann Parasitol. 2013;59(4):189\u201394.","journal-title":"Ann Parasitol"},{"key":"11315_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2018.06.059","volume":"79","author":"A Dhana","year":"2018","unstructured":"Dhana A, Yen H, Okhovat JP, Cho E, Keum N, Khumalo NP. Ivermectin versus permethrin in the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;79:943\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.059.","journal-title":"J Am Acad Dermatol"},{"key":"11315_CR26","doi-asserted-by":"publisher","unstructured":"Strong M, Johnstone PW. Interventions for treating scabies. Cochrane Database Syst Rev. 2007;CD000320. https:\/\/doi.org\/10.1002\/14651858.CD000320.","DOI":"10.1002\/14651858.CD000320"},{"issue":"1","key":"11315_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0253-7613.48882","volume":"41","author":"NP Bachewar","year":"2009","unstructured":"Bachewar NP, Thawani VR, Mali SN, et al. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and Ivermectin in patients with scabies. Indian J Pharmacol. 2009;41(1):9\u201314. https:\/\/doi.org\/10.4103\/0253-7613.48882.","journal-title":"Indian J Pharmacol"},{"key":"11315_CR28","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1001\/archdermatol.2008.513","volume":"144","author":"S Hu","year":"2008","unstructured":"Hu S, Bigby M. Treating scabies: results from an updated Cochrane review. Arch Dermatol. 2008;144:1638\u201340.","journal-title":"Arch Dermatol"},{"issue":"9","key":"11315_CR29","doi-asserted-by":"publisher","first-page":"HC01","DOI":"10.7860\/JCDR\/2014\/9092.4878","volume":"8","author":"PK Manjhi","year":"2014","unstructured":"Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral Ivermectin versus some topical antiscabies drugs in the treatment of scabies. J Clin Diagn Res. 2014;8(9):HC01\u20134. https:\/\/doi.org\/10.7860\/JCDR\/2014\/9092.4878.","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"11315_CR30","doi-asserted-by":"publisher","first-page":"e0009330","DOI":"10.1371\/journal.pntd.0009330","volume":"15","author":"P Behera","year":"2021","unstructured":"Behera P, Munshi H, Kalkonde Y, Deshmukh M, Bang A. Control of scabies in a tribal community using mass screening and treatment with oral ivermectin: a cluster randomized controlled trial in gadchiroli, India. PLoS Negl Trop Dis. 2021;15(4):e0009330. https:\/\/doi.org\/10.1371\/journal.pntd.0009330.","journal-title":"PLoS Negl Trop Dis"},{"key":"11315_CR31","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1500987","volume":"373","author":"L Romani","year":"2015","unstructured":"Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al. Mass drug administration for scabies control in a population with endemic disease. N Engl J Med. 2015;373:2305\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1500987.","journal-title":"N Engl J Med"},{"issue":"2","key":"11315_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/bjd\/ljad308","volume":"190","author":"L Mbuagbaw","year":"2024","unstructured":"Mbuagbaw L, Sadeghirad B, Morgan RL, et al. Failure of scabies treatment: a systematic review and meta-analysis. Br J Dermatol. 2024;190(2):163\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljad308.","journal-title":"Br J Dermatol"},{"issue":"6","key":"11315_CR33","doi-asserted-by":"publisher","first-page":"e15495","DOI":"10.1111\/dth.15495","volume":"35","author":"R Balestri","year":"2022","unstructured":"Balestri R, Magnano M, Infusino SD, Rizzoli L, Girardelli CR, Rech G. Use of oral Ivermectin in permethrin-resistant scabies: a pilot study. Dermatol Ther. 2022;35(6):e15495. https:\/\/doi.org\/10.1111\/dth.15495.","journal-title":"Dermatol Ther"},{"issue":"7","key":"11315_CR34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ad.2017.02.011","volume":"108","author":"J Sanz-Navarro","year":"2017","unstructured":"Sanz-Navarro J, Feal C, Dauden E. Treatment of human scabies with oral ivermectin: eczematous eruptions as a new non-reported adverse event. Actas Dermosifiliogr. 2017;108(7):643\u20139. https:\/\/doi.org\/10.1016\/j.ad.2017.02.011.","journal-title":"Actas Dermosifiliogr"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11315-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11315-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11315-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:54:35Z","timestamp":1757274875000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11315-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11315"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11315-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5323747\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by institutional review boards at the University of Dicle. All participants provided informed consent by checking a box on a self-administered online informed consent form indicating their agreement to participate in the study. All stages of the research were carried out in accordance with the current guidelines and regulations of ethics in research with human beings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"937"}}